Core Insights - Phathom Pharmaceuticals is set to present real-world data on its first-in-class treatment VOQUEZNA (vonoprazan) for gastroesophageal reflux disease (GERD) at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA [1][3] - VOQUEZNA is the only treatment approved by the U.S. FDA for adults for heartburn relief associated with Non-Erosive GERD and for treating all severities of Erosive Esophagitis (Erosive GERD) [1][34] - The data presented will analyze treatment patterns and patient characteristics, indicating VOQUEZNA's potential role for patients inadequately managed by existing therapies [3] Company Activities - Two Phathom-sponsored posters will be presented on May 5, 2025, at the conference, along with a Product Theater highlighting VOQUEZNA [2] - The company will maintain a strong presence at the conference with a booth (1743) on the exhibit floor [2] Industry Context - GERD affects approximately 1 in 5 U.S. adults, with around 70% of the GERD population suffering from Non-Erosive GERD [31][32] - Erosive GERD, affecting about 30% of the GERD population, can lead to severe complications if inadequately treated [33] - The conference will showcase over 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology [8]

Core Insights - Phathom Pharmaceuticals has partnered with Kenan Thompson to raise awareness about gastroesophageal reflux disease (GERD) through the "GERD IS NO JOKE" campaign, highlighting the importance of discussing treatment options with healthcare providers [1][7][10] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing innovative treatments for gastrointestinal diseases, specifically through its product VOQUEZNA (vonoprazan), which is the first FDA-approved potassium-competitive acid blocker (PCAB) for GERD management [23][20] - VOQUEZNA is approved for adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of Erosive Esophagitis, addressing a significant unmet need in the GERD patient population [20][18] Industry Context - Over 65 million people in the U.S. suffer from GERD, with approximately 70% having Non-Erosive GERD and 30% having Erosive GERD, indicating a large market potential for effective treatments [3][18] - The campaign aims to empower individuals with GERD to engage in open discussions with their healthcare providers about treatment options, particularly VOQUEZNA, which offers rapid and durable acid suppression compared to traditional medications [6][7]